Alphatec Holdings is trading 6.2% up at $8.78 after Stephens initiated coverage with an Overweight rating and a $15 price target, highlighting the company as a disruptor in spine surgery.
- The bullish analyst initiation from July 24, 2026, continues to drive investor interest and upward momentum.
- Stephens' price target suggests significant potential upside from current levels as the company gains traction in the medical technology sector.
- Shares are outperforming today despite mixed performance across broader market indices.